The short answer
Reta is informal shorthand for retatrutide. The full name follows WHO International Nonproprietary Name conventions: the -tide suffix denotes a peptide, and the preceding stem identifies its pharmacological class, -glutide marks a GLP-1 analogue, while -trutide marks the multi-receptor incretin agonists that retatrutide and tirzepatide belong to.
Key facts
- Reta
- Informal shorthand
- Full INN
- Retatrutide
- Development code
- LY3437943
- -tide suffix
- Denotes a peptide
- -glutide stem
- GLP-1 analogues
- -trutide stem
- Multi-receptor incretin agonists
How INN names are built
The WHO assigns International Nonproprietary Names using standardised stems that encode pharmacology. The suffix -tide marks a peptide. Within that, -glutide identifies GLP-1 analogues, which is why semaglutide, liraglutide and dulaglutide share it. Retatrutide and tirzepatide carry -trutide, marking the multi-receptor incretin agonists.
Why the naming system is useful
An unfamiliar drug name in a paper still tells you something. Anything ending -glutide is a GLP-1 analogue peptide. Anything ending -tide is a peptide at all. The stems are deliberately informative, which makes the system worth knowing rather than merely tolerating.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
INN versus development code
LY3437943 is Lilly's internal designation and appears in trial registrations and the discovery literature. Retatrutide is the INN, assigned as the compound progressed. Both refer to the same molecule, and searching both surfaces different records. The code finds earlier work, the INN finds later.
What an INN does not signify
Approval. An INN is assigned so a compound has one unambiguous generic name; it says nothing about regulatory status. DSIP holds an INN, emideltide, and is approved nowhere. Retatrutide holds one and is likewise approved nowhere.
Why the shorthand exists
Retatrutide is a mouthful, and abbreviated forms circulate in informal discussion. Reta carries no technical meaning and appears in no scientific literature. Searching for it finds forum and commercial content rather than research, in the same way TB-500 does.
Frequently asked questions
- What does the -tide suffix mean?
- That the compound is a peptide. Within that, -glutide marks GLP-1 analogues and -trutide marks multi-receptor incretin agonists.
- Is reta used in scientific literature?
- No. It is informal shorthand. Papers use retatrutide or the development code LY3437943.
- Does having an INN mean it is approved?
- No. An INN is a naming decision. DSIP holds one and is approved nowhere; so is retatrutide.
Extended research context
The Retatrutide Research deep dive
Deep dive: how the triple-agonist scaffold was engineered
Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance. This is the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.
The TRIUMPH Phase 3 programme in context
TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator (FDA, EMA, or MHRA) has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.
How retatrutide differs from tirzepatide and semaglutide at the mechanism level
Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press, but the pharmacology is more nuanced than the label implies.
Research applications
- ▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
- ▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
- ▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
- ▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
- ▸Reference material for teaching incretin pharmacology in university-level courses
Handling checklist
- ✓Store lyophilised vials at −20 °C; protect from light and humidity
- ✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
- ✓Once reconstituted, store at 2–8 °C and use within 28 days
- ✓Verify batch CoA: HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
- ✓Do not administer to humans or animals. Research use only
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Confusing retatrutide with tirzepatide in supplier catalogues
Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.
✗ Using tap or filtered water for reconstitution
Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water, never lab DI water.
✗ Storing reconstituted solution at room temperature
Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Is retatrutide the same molecule as LY3437943?
- What is the correct spelling: retatrutide or retatrutid?
- Is retatrutide a GLP-1 drug?
- Which company makes retatrutide?
- When will retatrutide be FDA approved?
- Is retatrutide legal in the UK?
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedCoskun T et al. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- WHOWHO: International Nonproprietary Nameswho.int
- PubMedJastreboff AM et al. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
The UK Peptides Editorial Team · Research library, UK Peptides
The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.
More Retatrutide Research articles
- What "Reta" on a Label Actually Tells YouAn informal term for material sold as retatrutide for laboratory research. What the name does and does not tell you about the contents.
- Retatrutide vs Mounjaro, Ozempic and WegovyMounjaro is tirzepatide, Ozempic is semaglutide, and retatrutide is neither. One, two and three receptors — and why the headline figures rarely compare.
- Is Retatrutide FDA Approved? Regulatory Status ExplainedRetatrutide is not FDA approved. It is an investigational peptide in the Phase 3 TRIUMPH programme. Current EMA, MHRA and FDA regulatory status explained.
- Retatrutide Molecular Structure and PropertiesA lipidated 39-mer supplied as a white lyophilised powder. What the structure implies for solubility, handling and analysis.
- What Is a Triple Agonist?One molecule activating three receptors. Why that differs from combination therapy, and what it buys and costs relative to giving three drugs.
Popular across the research hub
One flagship guide from every other research category.
- GHK-Cu (Copper Peptide)What Is Actually In a Copper Peptide Serum?
- TB-500 (Thymosin β4 fragment)TB-500 Side Effects: No Human Safety Record Exists
- BPC-157 (Pentadecapeptide)BPC-157 Structure and Sequence
- CJC-1295 & IpamorelinSynergy: A Word Worth Using Carefully
- Peptide ReferenceHPLC and Mass Spectrometry: What Each Answers
- Bacteriostatic WaterWhy Bacteriostatic Water Is the Default Peptide Diluent
- Research & Regulatory NewsThe Gap Is Smaller Outside the Trial, and It Widens With Time
- GLP-1 & Incretin ScienceWhat the Class Reliably Produces
- MOTS-c (Mitochondrial Peptide)MOTS-c and Exercise: What the Published Research Shows
- Semax (ACTH Fragment Peptide)Semax in the Published Literature
- Selank (Tuftsin Analogue)Selank Structure, Sequence and Physical Properties
- DSIP (Delta Sleep-Inducing Peptide)What Is DSIP? The Nonapeptide Named for an EEG Effect
- KLOW (Blend)What Is KLOW? KPV, GHK-Cu, BPC-157 and TB-500
- GLOW (Blend)One Volume, Three Peptides
- MT-2 (Melanotan II)What Before-and-After Photographs Can and Cannot Show
- IGF-1 LR3What Is IGF-1 LR3? Why It Is a Protein, Not a Peptide
- GlutathioneWhat Is Glutathione? The Bond That Makes It Unusual
- NAD+What Is NAD+? Structure, Role, and Why It Is Not a Peptide
- KPVWhat Is KPV? The Tripeptide From Alpha-MSH